Company Overview
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Recent Developments
- Mar 2026 Revenue of $8.26M (-71.6% YoY); net profit $-299.77M.
- Trailing 12 Months Year-on-year growth — revenue -33.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -19.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -19.07% |
| 1 Year: | -33.50% |
Stock Price Performance
| 1 Year: | +246.82% |
| 6 Months: | +40.47% |
| 3 Months: | +45.59% |
| 1 Month: | +14.14% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)72.54 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -19.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ROIV Roivant Sciences Ltd. R3KPHARMA | 41.48 | -88.26 | $29.96B | 0.00% | -9.49% | -8.52% | -19.07% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Dec 2020 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.58M | 1.32M | 5.75M | 7.74M | 13.99M | 24.34M | 4.32M | 12.53M | 17.05M | 21.62M | 3.65M | 15.56M | 7.99M | 4.47M | 9.02M | 2.17M | 1.57M | 2.00M | 1.44M |
| Operating Income | -114.45M | -156.54M | -259.07M | -154.39M | -684.43M | -246.02M | -282.31M | -280.77M | -378.08M | -276.41M | -213.89M | 5.13B | -102.23M | -341.71M | -274.38M | -284.92M | -306.23M | -339.15M | -365.99M |
| Net Income | -3.24M | -35.40M | -261.03M | -82.18M | -208.48M | -284.54M | -331.81M | -291.59M | -352.01M | -291.82M | -304.33M | 5.10B | 95.30M | -230.18M | 169.38M | -223.35M | -113.52M | -265.89M | -189.84M |
| Diluted EPS | - | - | - | -0.13 | -0.32 | -0.41 | -0.48 | -0.42 | -0.49 | -0.38 | -0.40 | 6.03 | 0.12 | -0.31 | 0.23 | -0.33 | -0.17 | -0.38 | -0.26 |
| R&D Expense | 58.73M | 97.41M | 202.26M | 78.52M | 132.10M | 137.34M | 135.83M | 132.00M | 125.53M | 125.13M | 114.79M | 108.15M | 120.51M | 143.07M | 141.59M | 152.92M | 164.57M | 165.38M | 202.02M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 23.80M | 55.29M | 31.53M | 32.71M | 29.05M | 8.26M |
| Operating Income | -1.07B | -1.35B | -906.76M | 4.50B | -1.00B | -515.07M |
| Net Income | -809.23M | -845.26M | -1.01B | 4.35B | -171.98M | -299.77M |
| Diluted EPS | - | -1.26 | -1.42 | 5.23 | -0.24 | -0.54 |
| R&D Expense | 236.63M | 483.04M | 454.06M | 439.91M | 550.41M | 681.81M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.59B | - | 2.39B | 7.22B | 5.44B | 5.71B |
| Current Assets | - | - | - | 1.80B | 6.73B | 5.00B | 5.17B |
| Cash & Equivalents | - | 2.06B | - | 1.68B | 6.49B | 2.72B | 1.42B |
| Inventory | - | - | 0 | 2.76M | 35.25M | - | - |
| Receivables | - | - | 3.88M | 30.38M | 53.55M | - | - |
| Total Liabilities | - | 527.69M | - | 782.02M | 773.95M | 249.74M | 416.27M |
| Current Liabilities | - | 218.96M | - | 272.45M | 266.76M | 149.41M | 281.24M |
| Long Term Debt | - | 170.28M | 210.03M | 375.51M | 430.59M | - | - |
| Total Debt | - | - | - | 481.40M | 53.99M | 100.17M | 107.44M |
| Total Equity | 2.09B | 1.80B | - | 1.16B | 5.97B | 4.69B | 4.53B |
| Shares Outstanding | - | - | - | 760.14M | 806.68M | 695.94M | 720.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -552.14M | -677.73M | -843.39M | -765.27M | -839.45M | -750.35M |
| Investing Cash Flow | -31.70M | 303.30M | -44.27M | 5.20B | -1.77B | -682.33M |
| Financing Cash Flow | 456.26M | 306.79M | 499.46M | 419.36M | -1.22B | 134.24M |
| Capital Expenditure | -5.81M | -17.44M | -12.69M | -1.38M | -4.60M | -8.21M |
| Free Cash Flow | -557.94M | -695.16M | -856.08M | -766.65M | -844.05M | -758.56M |
| Share Buybacks | - | - | 0 | 0 | 1.29B | - |
Ratios (Annual)
Figures in %.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -4,500.5% | -2,444.8% | -2,875.9% | 13,746.9% | -3,453.3% | -6,235.7% |
| Net Margin % | -3,400.9% | -1,528.9% | -3,200.2% | 13,294.2% | -592.0% | -3,629.2% |
| ROE % | -45.0% | - | -87.2% | 72.9% | -3.7% | -6.6% |
| ROCE % | -45.2% | - | -42.8% | 64.7% | -19.0% | -9.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 11.22% | 81.02M | $3.22B |
| 2 | Blackrock Inc. | 6.68% | 48.24M | $1.92B |
| 3 | Morgan Stanley | 5.90% | 42.59M | $1.69B |
| 4 | QVT Financial LP | 3.28% | 23.72M | $943.47M |
| 5 | Vanguard Capital Management LLC | 3.06% | 22.12M | $879.84M |
| 6 | Vanguard Portfolio Management LLC | 3.00% | 21.64M | $860.68M |
| 7 | Goldman Sachs Group Inc | 2.57% | 18.56M | $737.99M |
| 8 | State Street Corporation | 2.46% | 17.80M | $707.75M |
| 9 | UBS Group AG | 2.42% | 17.47M | $694.65M |
| 10 | Farallon Capital Management LLC | 1.98% | 14.31M | $569.07M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ROIV
Why Is ROIV Stock Tracking Record Highs In Pre-Market Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOeC1YaVRrNEg4LXlsS2UzMHRRQnhVWWtvZzFrWFpzblQ0cTVWdG1QWUY2bFNIRkJhRHNMc09ZQ2p3VDhCU25rMWptWVhISUxmSEVkbnZ4eGQyMG9ZVnRya1VOby1EcTV2ZENwamNNc0NoNGxDa1lvWGNPdzB1UjAxa3dxMUEzUmk5NnNROX…
Roivant Sciences (NASDAQ: ROIV) director moves to sell shares after option exercise - Stock Titan
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNRGFGUlFwcEhORlgwWnhUVVRWWU5vUlN2cWd6Ylp5UmhMWTdhY0pMaEFUcUd1QUV1MTlKRkFMdEhQQXFHLUNhbExJQlA1UE1XMTJ5bkM2TGNwSExDeUE3WUtTZWEwWno4NGVCd1BZZHR4UU1LSFd6UmYzc1ZoemdfaURSbkJ2bWV4Z3VVTH…
ROIV Stock Jumps As FDA Clears LISRAYA And Analysts Hike Targets - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE1DM05JQk1xeUw2azFTbWlBa1NvWU84eXVMWTRpTVdMb0xENEwwLUNfUzViMUV2RFVvWlNoR3VZX1RybF9ZLUVfcVR6a3BKaURVenBvMERacjJEX0M4RWVYOVNXUFF1NlpocTRoX3YzaXViTXc3Q2pDNGNMak9hQQ?oc=5" target="_blan…
Stocks making the biggest moves premarket: Peloton Interactive, Roivant Sciences, Boston Scientific & more - CNBC
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOSGhGSEVieUI3azZiRW0tbjBLdHE3R29KNFVHUXRIWXo0OFZqenRXblYtSUppY1RycW9vUWY1UFBtWHlYRG9zdmVsQ21vY192T3UwVVR4c3RoTkVHLVRqX3FWTHBoSGQ4VkdUQm9QMmhiYXk1eEpwcVRqNmlvMVQ4Z05uc1FzejU4S0F5OU…
ROIV Stock Jumps As LISRAYA FDA Approval Ignites Momentum - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE0wdE84c3lReW4xaXpQWFR1d3V3a0dneHVpNmFnX2w0T0FkZ3YxNGJ3RDJGbi1iZzUyaDZNVi1RdWo3WkdKTHNRTGlHR1B1OTFIdlFjWFZ5Qm8wdGZ2U3k5c29ydnI5azRjemRmMG13Q1lWemRYWTMxdlBucVA?oc=5" target="_blank">…
Roivant Sciences Rallies as Mosliciguat Phase 2 Data Beat Key Endpoints - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNNW5xMGFfUTc5eVdVRnBHSUVaRl9QSXFNR2k1YjhHTWNHaW5CNmpoV1VRa3A3N2RjMTVqc2ZHN0NtNS1PVDc3R3VkNE1BM3piZjhPekYybnhvR21fWHVrcDFGREpxbnlpejdtOU9ndXo3aVozMmg0ZHBtQmdLbkRHNEc5WXZoQWlzaHVEMX…
ROIV — Frequently Asked Questions
What is the current share price of Roivant Sciences Ltd. (ROIV)?
As of 2026-09-19 21:16 PDT, Roivant Sciences Ltd. (ROIV) trades at $41.48 on NasdaqGS. Its 52-week range is $11.64 to $41.48.
What is the market capitalisation of ROIV?
Roivant Sciences Ltd. (ROIV) has a market capitalisation of $29.96B on NasdaqGS.
What is the P/E ratio of ROIV?
ROIV trades at a trailing price-to-earnings (P/E) ratio of -88.26. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 6.79.
What is the return on equity (ROE) of ROIV?
ROIV has a return on equity (ROE) of -8.52%. Its return on capital employed (ROCE) is -9.49%.
Is ROIV a good stock to buy?
This page provides a data-driven analysis of Roivant Sciences Ltd. (ROIV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.